Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEUS: Ziltivekimab in ASCVD with CKD and Systemic Inflammation
jRCT2021210033Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Sep 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease, chronic kidney disease (CKD), chronic inflammation and 3 more comparing Ziltivekimab 15 mg s.c. + standard of care with Placebo s.c. + standard of care (2 arms). Primary endpoint: Time to first 3-point MACE. Started Sep 2021; status: active, not recruiting.
02
Drugs
ziltivekimab
03
Conditions
atherosclerotic diseasechronic kidney disease (CKD)chronic inflammationmyocardial infarction (MI)stroke
Beyond the preview
Go deeper on jRCT2021210033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021210033.